Metabolomics-Based Clinical Efficacy and Effect on the Endogenous Metabolites of Tangzhiqing Tablet, a Chinese Patent Medicine for Type 2 Diabetes Mellitus with Hypertriglyceridemia

Table 5

The changes comparison of the peak intensity of the potential biomarkers before and after treatment in two groups (mean ± S.D.).

Biomarkers	TZQ Group (n=15)			Placebo Group (n=15)
	Before treatment	After treatment	p	Before treatment	After treatment	p
D-Galactose	2097.23±555.64	1796.80±1050.53	0.610	2217.10±464.44	2486.60±1038.89	0.579
UDP-glucose	1220.75±685.75	468.26±308.37	0.155	682.36±217.58	882.12±213.60	0.086
L-Leucine	3490.38±274.78	3397.90±76.80	0.470	3505.53±239.78	4093.26±1029.48	0.331
L-Tyrosine	1667.88±208.55	1573.02±135.06	0.276	1579.23±185.80	1847.48±480.83	0.237
LysoPC(16:0)	9833.36±1318.86	3633.52±1197.10	<0.001	6021.73±1873.12	5961.09±4533.85	0.969
LysoPC(18:0)	751.23±118.43	742.64±381.31	0.958	863.39±81.89	850.71±315.53	0.926
LysoPC(18:3)	18365.49±1468.24	8804.01±1598.84	<0.001	16399.05±1399.12	15440.55±4240.13	0.513
LysoPC(14:1)	626.84±296.06	157.11±18.67	0.026	517.33±293.07	299.37±381.13	0.294
PC(15:0/20:2)	781.42±142.81	489.05±169.67	0.001	840.39±64.15	893.06±417.55	0.778
PC(16:0/22:4)	7471.85±2200.75	3462.13±407.02	0.015	6396.02±2356.44	4846.48±1015.19	0.222
PC(14:0/14:1)	1081.27±366.46	186.24±47.03	0.005	1062.27±340.92	1141.66±292.78	0.665
PE(14:0/18:4)	816.29±661.96	226.31±196.64	0.198	360.05±91.35	511.65±125.01	0.124
PE(14:0/20:4)	1659.73±611.85	642.14±142.21	0.026	1867.68±441.45	1896.16±1102.87	0.966
DG(22:0/20:5)	1171.63±515.18	365.11±60.69	0.017	935.65±219.09	916.33±549.78	0.952
DG(15:0/18:3)	1549.78±708.90	415.63±292.41	0.007	779.78±508.12	835.61±482.38	0.860
Sphinganine	3594.59±5522.04	1203.80±287.44	0.396	1302.85±151.44	1205.19±355.10	0.451
Cholest-5-ene	28.69±29.76	37.82±34.07	0.341	7.89±4.14	17.73±18.12	0.326

Note: data were analyzed using paired t-test.